Cargando…

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma

BACKGROUND: Immune checkpoint (IC) blockades (ICBs) significantly improve patients’ clinical outcomes with solid tumors. Because the objective response rate of single-agent ICB is limited, it is meaningful to explore the combination of ICs for immunotherapy. METHODS: RNA sequencing data of 95 newly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Peipei, Chen, Yueyun, Long, Qingqin, Li, Qing, Tian, Jiangfang, Liu, Ting, Wu, Yong, Ding, Zhenyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504357/ https://www.ncbi.nlm.nih.gov/pubmed/34625514 http://dx.doi.org/10.1136/jitc-2021-002836

Ejemplares similares

Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
por: Li, Gaopeng, et al.
Publicado: (2021)

CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
por: van den Bulk, Jitske, et al.
Publicado: (2023)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
por: Ascierto, Paolo A, et al.
Publicado: (2022)

TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8(+) T cell and XCR1(+) dendritic cell spatial co-localization
por: Gardner, Alycia, et al.
Publicado: (2022)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
por: Simon, Sylvain, et al.
Publicado: (2020)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
por: Lv, Tingting, et al.
Publicado: (2022)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

DEK overexpression is predictive of poor prognosis in esophageal squamous cell carcinoma
por: Yi, Huochun, et al.
Publicado: (2019)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers
por: Hu, Chunhong, et al.
Publicado: (2021)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
por: Shen, Yang, et al.
Publicado: (2020)

A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
por: Sánchez-Alonso, Santiago, et al.
Publicado: (2020)

Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation
por: Wu, Bogang, et al.
Publicado: (2020)

Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
por: Pearce, Hayden, et al.
Publicado: (2023)

Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma
por: Zhou, Jiayi, et al.
Publicado: (2021)

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
por: Guerin, Marion v, et al.
Publicado: (2020)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1
por: Sugiyarto, Gessa, et al.
Publicado: (2023)

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1
por: Chen, Zhanfei, et al.
Publicado: (2020)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation
por: Qin, Rui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3rq2jfsi9v00duraebef56bpsb